Belgium· BE-AMP-SAM575662-00
Cosentyx 300 mg
A secukinumab product containing secukinumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Secukinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC10 (secukinumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Secukinumab · ATC L04AC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of secukinumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Secukinumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.03
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Secukinumab
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- L04AC10
- ATC class
- Secukinumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
2 priced- be_apb4285482EUR 998.3
- be_apb4285490EUR 2909.56
- be_apb7732191
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
150 interactions on record for secukinumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Secukinumab · interactions on record
150 records
- 27 severe
- 116 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Secukinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCOSENTYXNovartis Europharm Limited, Dublin
- IcelandCosentyxNovartis Europharm Limited*
- SwedenCosentyx 300 mg Injektionsvätska, lösning i förfylld injektionspennaNovartis Europharm Limited
- NorwayCosentyxNovartis Europharm Limited (1)
- PolandCosentyxNovartis Europharm Limited
- SpainCOSENTYX 300 MG SOLUCION INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- United StatesCOSENTYXNovartis Pharmaceuticals Corporation
- SwitzerlandCosentyx
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cosentyx
- Liechtenstein · Cosentyx
- Norway · Cosentyx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3f55f80-5b6a-40db-baac-57c822eaee5b GET /v1/drugs/b3f55f80-5b6a-40db-baac-57c822eaee5b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Cosentyx 300 mg",
"name_fr": "Cosentyx 300 mg",
"name_nl": "Cosentyx 300 mg",
"amp_code": "SAM575662-00",
"strengths": [
"150.0000"
],
"pack_count": 2,
"substances": [
"Secukinumab",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Secukinumab",
"authorisation_numbers": [
"EU/1/14/980/010",
"EU/1/14/980/011"
]
}See everything about secukinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.